Centessa Pharmaceuticals Plc ADR (CNTA)

Mar 6, 2025, 4:14 PM EST - 2 days ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Jan 8, 2025, 7:05 AM EST - 2 months ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Dec 26, 2024, 12:31 PM EST - 2 months ago

Centessa: Shift In Focus With ORX750 Development Continues To Pay Off

Nov 12, 2024, 7:00 AM EST - 4 months ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Sep 26, 2024, 6:00 AM EDT - 5 months ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Sep 12, 2024, 10:34 PM EDT - 6 months ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Sep 11, 2024, 4:04 PM EDT - 6 months ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Sep 11, 2024, 6:52 AM EDT - 6 months ago

Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Sep 10, 2024, 7:00 AM EDT - 6 months ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Aug 27, 2024, 8:00 AM EDT - 6 months ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Aug 21, 2024, 8:00 AM EDT - 7 months ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 13, 2024, 7:00 AM EDT - 7 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Jun 10, 2024, 7:00 AM EDT - 9 months ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

May 21, 2024, 8:45 AM EDT - 10 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 13, 2024, 4:10 PM EDT - 10 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Apr 24, 2024, 2:20 PM EDT - 11 months ago

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 23, 2024, 9:36 PM EDT - 11 months ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Apr 23, 2024, 4:17 PM EDT - 11 months ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Apr 22, 2024, 7:00 AM EDT - 11 months ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Mar 28, 2024, 4:28 PM EDT - 1 year ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Feb 9, 2024, 7:00 AM EST - 1 year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Feb 5, 2024, 1:48 PM EST - 1 year ago

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

Dec 13, 2023, 8:00 AM EST - 1 year ago

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Dec 10, 2023, 12:05 PM EST - 1 year ago

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Nov 13, 2023, 4:05 PM EST - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Nov 2, 2023, 9:09 AM EDT - 1 year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Sep 14, 2023, 5:31 AM EDT - 1 year ago

Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets

Aug 23, 2023, 5:08 PM EDT - 1 year ago

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Aug 17, 2023, 11:58 AM EDT - 1 year ago

Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Jul 10, 2023, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

May 22, 2023, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

May 12, 2023, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Mar 23, 2023, 4:30 PM EDT - 2 years ago

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

CLVT

Mar 1, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

Feb 6, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Feb 2, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 9:08 AM EST - 2 years ago

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Dec 10, 2022, 3:30 PM EST - 2 years ago

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Nov 28, 2022, 10:30 PM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses to Contact the Firm

Nov 28, 2022, 11:30 AM EST - 2 years ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Nov 25, 2022, 9:10 AM EST - 2 years ago

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Nov 24, 2022, 9:05 AM EST - 2 years ago

MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Nov 22, 2022, 2:30 PM EST - 2 years ago

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm